An interventional study of DexCom G6 in Type 2 Diabetes, sponsored by Kathleen Dungan. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Kathleen Dungan · Not applicable, Interventional, and Treatment
In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 108 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Kathleen Dungan is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: DexCom G6
Wearable continuous glucose monitor
Change in TIR 70-180 mg/dl
Change in %time in range between 70-180 mg/dl from 2 weeks to 12 weeks.
Time frame: 12 weeks
% Wear Time >70%
The number of participants with % wear time \>70% will be reported.
Time frame: 12 weeks
DTSQc Score
The DTSQc compares the experience of the current treatment with the experience of the treatment before initiation of the study. Scores range from +3 ("much more satisfied now") to -3 ("much less satisfied now"), with 0 (midpoint) representing no change. Higher scores on the DTSQ total score indicate higher treatment satisfaction, and lower scores indicate lower treatment satisfaction. The total score ranges from -18 (maximum deterioration in satisfaction) to +18 (maximum improvement in satisfaction).A score of 0 indicates no change in satisfaction.
Time frame: 12 weeks
| Milestone | Dexcom CGM |
|---|---|
| Started | 108 |
| Completed | 66 |
| Not completed | 42 |
Change in %time in range between 70-180 mg/dl from 2 weeks to 12 weeks.
| percentage of time spent 70-180 mg/dl | Dexcom CGM |
|---|---|
| Change in TIR 70-180 mg/dl | 8.5 ± 28 |
The number of participants with % wear time \>70% will be reported.
| Participants | Dexcom CGM |
|---|---|
| % Wear Time >70% | 54 |
The DTSQc compares the experience of the current treatment with the experience of the treatment before initiation of the study. Scores range from +3 ("much more satisfied now") to -3 ("much less satisfied now"), with 0 (midpoint) representing no change. Higher scores on the DTSQ total score indicate higher treatment satisfaction, and lower scores indicate lower treatment satisfaction. The total score ranges from -18 (maximum deterioration in satisfaction) to +18 (maximum improvement in satisfaction).A score of 0 indicates no change in satisfaction.
| score on a scale | Dexcom CGM |
|---|---|
| DTSQc Score | 8 (6 to 12) |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexcom CGM | 1/108 (0.9%) | 0/108 (0%) | 30/108 (27.8%) |
| Event | Dexcom CGM |
|---|---|
| Sensor eventSkin and subcutaneous tissue disorders | 30/108 |
| Age, Categorical(Participants) | Dexcom CGM |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 92 |
| >=65 years | 16 |
| Age, Continuous(years) | Dexcom CGM |
|---|---|
| Mean | 52.3 ± 10.9 |
| Sex: Female, Male(Participants) | Dexcom CGM |
|---|---|
| Female | 48 |
| Male | 60 |
| Ethnicity (NIH/OMB)(Participants) | Dexcom CGM |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 106 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Dexcom CGM |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 62 |
| White | 46 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Dexcom CGM |
|---|---|
| United States | 108 |
| Baseline HbA1c(percentage of glycosylated hemoglobin) | Dexcom CGM |
|---|---|
| Mean | 11.3 ± 2.0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — • Availability of data and materials: In accordance with institution policy on sharing data and research resources, the final research data from this study may be made available for research purposes under a limited data use agreement specifying criteria for data access, conditions for research use, privacy and confidentiality standards to ensure data security and prohibitions for manipulating data for the purposes of identifying subjects.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kathleen Dungan